Stevanato Group Spa Stock

$24.94

1.31% today

NYSE, Jul 30, 10:10 pm CET

ISIN

IT0005452658

Symbol

STVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Stevanato Group Spa Stock price

$25.27

+5.60 28.47% 5Y

NYSE, Closing price Tue, Jul 29 2025

-0.70 2.70%

ISIN

IT0005452658

Symbol

STVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$6.9b

Enterprise Value

$7.3b

Net debt

$382.0m

Cash

$113.5m

Shares outstanding

273.0m

Valuation (TTM | estimate)

P/E

49.5 | 40.5

P/S

5.4 | 5.0

EV/Sales

5.7 | 5.3

EV/FCF

negative

P/B

4.3

Dividends

DPS

$0.06

Yield 1Y | 5Y

0.2% | 0.2%

Growth 1Y | 5Y

7.1% | -

Payout 1Y | 3Y

12.4% | 10.1%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$1.3b | $1.4b

EBITDA

$223.6m | $343.8m

EBIT

$208.7m | $228.8m

Net Income

$136.3m | $170.2m

Free Cash Flow

$-182.5m

Growth (TTM | estimate)

Revenue

1.7% | 8.6%

EBITDA

-15.8% | 53.5%

EBIT

-16.3% | 9.4%

Net Income

-18.8% | 24.9%

Free Cash Flow

53.1%

Financial Health

Equity Ratio

60.3%

Return on Equity

8.4%

ROCE

9.8%

ROIC

7.1%

Debt/Equity

0.3

EPS

$0.5

FCF per Share

$-0.7

Short interest

4.5%

Employees

Rev per Employee

$230.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Stevanato Group Spa forecast:

13x Buy

76%

4x Hold

24%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Stevanato Group Spa forecast:

Buy

76%

Hold

24%

Analyst Estimates with Stock Price Targets

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	1,275 1,275	2% 2% 100%
- Direct Costs	909 909	7% 7% 71%
Gross Profit	366 366	9% 9% 29%
- Selling and Administrative Expenses	120 120	4% 4% 9%
- Research and Development Expense	33 33	9% 9% 3%
EBITDA	224 224	16% 16% 18%
- Depreciation and Amortization	15 15	7% 7% 1%
EBIT (Operating Income) EBIT	209 209	16% 16% 16%
Net Profit	136 136	19% 19% 11%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Stevanato Group Spa Stock News

Neutral

Business Wire

●

7 days ago

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are inte...

Neutral

Business Wire

●

8 days ago

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Co...

Positive

Seeking Alpha

●

8 days ago

Stevanato: Expansion In Italy And The U.S. Will Pave The Way

The new facility in the U.S. expects to generate €500 million in annual revenues by 2028. The global drug containment solution market is expected to grow at an 8% CAGR from 2024 to 2030. In this market, Stevanato has a competitive advantage. Stevanato's PP&E has increased by 304.61% between 2018 and Q1 2025, indicating the significant investment that the company has dedicated to expanding its o...

More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office	Italy
CEO	Franco Stevanato
Employees	5,635
Founded	1996
Website	www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now